The 100% Pharma Tariff Is 15% Where It Counts (August 2026): Section 232 Went Live on 31 July — What It Means for the Franc and the Euro

The largest single tariff rate the United States has imposed on any traded good took effect on 31 July 2026, and almost nobody will pay it. Proclamation 11020 put a 100% duty on patented pharmaceuticals, their active ingredients and key starting materials — but the same document caps the rate at 15% for the European Union, Japan, South Korea, Switzerland and Liechtenstein, and at 10% for the United Kingdom. Those caps happen to cover Ireland, Germany, Belgium and Switzerland: the origins that supply most of what the US actually imports. And the 90% of American prescriptions filled with generics sit outside the action entirely, on a separately announced schedule that holds them at zero until August 2028. The headline number is 100%. The number that will show up in landed costs, corporate margins and eventually in export receipts is 15%.

This is the gap that matters for anyone trying to read a policy headline into a price. A 100% duty on a category where the US ran a $112bn deficit in 2025 would be a genuine macro event — a terms-of-trade shock for Switzerland and Ireland, a measurable inflation impulse in the US, a reason for two currencies to reprice. A 15% duty on the same category, with a zero-rate pathway for companies that sign pricing agreements and a 20% pathway for companies that commit to build in the US, is a corporate margin negotiation conducted through the tariff schedule. Both are real. Only one of them reaches an exchange rate.

What actually took effect on 31 July

The instrument is Proclamation 11020, signed on 2 April 2026 and titled "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States." It rests on Section 232 of the Trade Expansion Act of 1962 — the national-security authority, the same one used for steel, aluminium and autos — on a finding that pharmaceutical import dependence threatens to impair US national security. The full text is on the White House site and in the Federal Register.

The covered goods are narrower than "medicines." The duty attaches to patented pharmaceutical articles listed in the FDA's Approved Drug Products publication (the Orange Book) or its Licensed Biological Products list (the Purple Book), plus the active pharmaceutical ingredients and key starting materials for those articles. Generic pharmaceuticals and biosimilars are out. So are US-origin products, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates and animal health products.

The timing runs in two tranches, keyed to the signing date. Companies named in Annex III came under the duty on 31 July 2026 — 120 days after 2 April. Everyone else importing covered goods comes under it on 29 September 2026, at 180 days. That two-month gap is the negotiating window, and it is the reason the market response to 31 July was muted: the measure is not yet economy-wide.

The rate ladder: why 100% is the exception

Read the rate structure as a ladder rather than a single number and the economics change completely.

The 15% band is the decisive row. It exists because pharmaceutical treatment was written into the trade arrangements those economies concluded with Washington, and it applies to the origins that dominate the trade. Switzerland's inclusion was confirmed in Swiss coverage of the measure at the time (SWI swissinfo.ch). Neutral coverage of the original announcement: Al Jazeera.

What has to be true for the 100% rate to matter macroeconomically? A large share of US branded-drug imports would have to originate outside the capped list and belong to companies with neither an HHS pricing agreement nor an approved onshoring plan. On the 2025 trade data, that share is small.

The generic clock that started today

The second leg landed in late July 2026, and it is the one with the larger long-run consumer footprint. Generic drugs imported into the United States stay at a 0% rate from 1 August 2026 for two years; the rate then rises to 100% from 1 August 2028 for one year, and to 200% from 1 August 2029. The stated purpose is to give manufacturers a fixed window to move production onshore, with the escalating rates functioning as the penalty for not doing so (Bloomberg).

The asymmetry between the two legs is the single most useful thing to understand about this policy. Generics are roughly 90% of prescriptions filled in the United States but only about 12% of prescription drug spending (FDA), and roughly 70% of that supply comes from abroad — India above all. So:

That is why a reader should be sceptical of any claim that pharmaceutical tariffs are an imminent US inflation story. The leg that would reach the pharmacy counter is priced at zero for two more years. The leg that is live reaches corporate income statements first, and reaches consumer prices only to the extent that branded manufacturers pass 15 percentage points of landed cost through a payer system that negotiates on rebates rather than on list.

Where the exposure actually sits

The trade data explains why this is a European and Swiss story before it is anything else.

Eurostat reports that the EU exported €366.2bn of medicinal and pharmaceutical products in 2025 against €145.7bn of imports — a record €220.5bn surplus, with exports up 16.0% on 2024. The United States took 43.8% of all extra-EU shipments, worth €160.6bn. Within the EU, Ireland was the largest extra-EU exporter at €93.8bn, ahead of Germany at €67.9bn and Belgium at €38.5bn (Eurostat).

Switzerland is the other pole. Chemicals and pharmaceuticals now account for roughly 53% of total Swiss goods exports, and pharmaceutical active ingredients and specialities made up about 94.7% of the Swiss chemical and pharmaceutical sector's exports to the United States in 2025. Switzerland was the third-largest single-country source of US pharmaceutical imports last year at roughly $19bn, behind Ireland and Germany, in a US market that imported on the order of $200bn of pharmaceutical products against a $112bn sector deficit.

Concentration of that kind usually means high tariff sensitivity. Here it does not, because the rate is capped. An economy that sends most of one dominant export sector to a single destination is exposed to the rate, and the rate is 15%.

The channel to the franc

The Swiss franc is where a naive reading goes wrong most often. The chain of reasoning that fails is: Switzerland is a pharma economy, the US tariffed pharma, therefore sell the franc.

Work the channels separately instead. The interest-rate factor is untouched — the Swiss National Bank's policy rate is 0% and Swiss inflation was running near 0.5% in June, well inside target, so a duty on one export sector changes nothing about the differential that actually prices CHF crosses. The risk factor is untouched, and arguably points the other way: trade-policy escalation is a mild risk-off input, and the franc is a beneficiary of risk-off, not a victim of it. The growth factor takes a small, genuine hit through export margins. And the balance-of-payments channel — the structural surplus that has underwritten franc strength for decades — is far too large for a 15% duty on part of one sector to reverse.

USD/CHF sat near 0.8171 on 30 July 2026, and the franc's 2026 story has been about something else entirely: as we covered in the dollar beating the franc at its own game, the safe-haven bid has been going to the currency that pays a yield. The tariff does not change that ranking. For the broader framework, see what drives the Swiss franc.

The channel to the euro

For the euro, the arithmetic is larger in absolute terms and smaller in relative terms. €160.6bn of pharmaceutical exports to the US is a serious number, but it sits inside a monetary union whose total exports dwarf it, and the 15% cap applies union-wide.

The distortion worth naming is Irish. Ireland's €93.8bn of extra-EU pharmaceutical exports is enormous relative to the size of the Irish economy and reflects the transfer-pricing and contract-manufacturing structures that make Irish GDP a poor measure of Irish activity. A tariff on those flows is therefore first a corporate-structure question and only second a euro-area growth question. It will show up in Irish trade statistics with a violence that will not be matched in euro-area aggregate demand.

The euro's own drivers this summer have run through inflation and the rate path rather than trade policy — the July flash and the German print did more to the currency in a morning than this proclamation has done in four months. The tariff belongs in the growth factor at the margin, not in the rate factor.

What would change the picture

Four dates and one legal risk, in order of proximity.

29 September 2026 is the real switch. It ends the company-by-company phase and applies the duty to every remaining importer of covered goods. If the capped rates hold, this is a widening of coverage at 15%, which is a manageable step. If any cap lapses before then, the same date becomes something much bigger.

The onshoring pathway converts tariff exposure into US capital expenditure, at 20% until April 2030 for approved plans. Watch the count of approvals rather than the rhetoric: each one is a company choosing to change its physical footprint instead of paying, and in aggregate that shifts the composition of the US trade deficit over years, not quarters.

20 January 2029 is when the Annex II zero-rate expires for the 13 companies that signed HHS pricing agreements early. That is a cliff for a specific set of firms.

1 August 2028 is the generic cliff, and the one a macro reader should diarise. That is when the inflation channel this policy has so far avoided would actually open, because it reaches the 90% of prescriptions that the branded action does not touch.

The legal risk sits underneath all of it. Section 232 rests on a national-security finding, and US tariff actions across this cycle have been litigated with real consequences — the broader tariff architecture was already reshaped once this year by court action, which is why the current base layer arrived via a different statute, as we set out in the July tariff-cliff piece. A tariff schedule that can be vacated is a tariff schedule the FX market discounts.

The takeaway

The most useful habit this story rewards is the one that reads the annex before the headline. A 100% tariff on pharmaceuticals sounds like a terms-of-trade shock for two of Europe's most concentrated export economies and an inflation shock for the United States. Read the instrument and it is a 15% duty on the origins that matter, zero for the companies that signed pricing agreements, 20% for the companies that agreed to build, and nothing at all on the 90% of American prescriptions that are generic — until 2028.

That is not a claim that the policy is small. It is a claim about where it lands. It lands on the income statements of large branded manufacturers and on the Irish and Swiss trade accounts, and it lands there as a margin compression measured in single-digit billions rather than as a volume collapse. Margin compression does not move an interest-rate differential, does not move a risk premium, and does not move a current-account surplus that has been structural for thirty years. So it does not, on its own, move the franc or the euro.

What would move them is a change in the rate rather than a change in the coverage: a cap renegotiated upward, a court ruling that resets the whole architecture, or the 2028 generic schedule arriving on time. Until one of those happens, the correct read of the 31 July headline is that the largest tariff rate the United States has ever applied to a traded good is, in practice, its fifth-largest — and the distance between those two facts is the entire trade.

To learn how Pip Theory builds its fundamental currency-strength scores, see the methodology overview.

Educational macro context only — not investment advice.